On May 21, 2026, India’s Central Drugs Standard Control Organisation (CDSCO) issued a clear directive: no injectable product can be classified or sold as a cosmetic. The directive, reported by CNBC TV18, India Today, The Times of India, and multiple other outlets, targets the growing trend of beauty clinics offering “skin boosters,” filler injections, and other injectable treatments under the guise of cosmetic procedures.
💉 What the CDSCO Directive Says
The CDSCO’s position is straightforward: under India’s Drugs and Cosmetics Act, 1940, any product that is injected into the human body is classified as a drug, not a cosmetic. This means injectable treatments — regardless of how they are marketed — must meet the same regulatory standards as pharmaceutical drugs, including manufacturing approvals, quality testing, and valid medical prescriptions.
The directive explicitly states that no cosmetic is permitted to be introduced into the human body through injection. Any clinic or practitioner offering injectable “cosmetic” treatments is operating outside the law unless the product in question has been approved as a drug by the CDSCO.
🧪 Why This Matters: The Cosmetic vs. Drug Distinction
India’s legal framework draws a sharp line between cosmetics and drugs:
- Cosmetics (under the Cosmetics Rules, 2020) are products applied topically for cleansing, beautifying, or altering appearance — creams, lotions, makeup, shampoos, and similar external-use products.
- Drugs (under the Drugs and Cosmetics Act, 1940) include any substance intended to be used internally or externally for therapeutic, diagnostic, or physiological purposes — including any substance injected into the body.
The key takeaway: once a product crosses the skin barrier via injection, it is no longer a cosmetic — it is a drug, and must be regulated as one.
⚠️ The Risks of Unregulated Injectable “Cosmetics”
The CDSCO’s crackdown addresses several serious concerns:
- Unapproved substances: Many injectable “skin boosters” and “fillers” used in beauty clinics contain substances that have not been evaluated or approved by the CDSCO for human injection.
- Sterility and safety: Injections administered outside clinical settings may not follow proper sterile protocols, increasing the risk of infections, allergic reactions, and tissue damage.
- Lack of medical oversight: Beauty clinics are not equipped to handle adverse reactions to injectable substances, which can range from mild swelling to serious complications requiring emergency medical care.
- Counterfeit products: The unregulated market creates opportunities for counterfeit or substandard injectable products to enter the supply chain.
✅ How to Protect Yourself as a Consumer
If you are considering any injectable treatment, follow these practical steps:
- Verify the product: Ask for the product name and check whether it has CDSCO approval. Legitimate injectable drugs (such as FDA/CDSCO-approved fillers or botulinum toxin products) will have clear regulatory approval documentation.
- Consult a qualified medical professional: Injectable treatments should only be administered by registered medical practitioners (MBBS or higher) in clinical settings, not by beauticians or aestheticians.
- Check the facility: Ensure the procedure is performed in a clinic or hospital that follows sterile injection protocols and has emergency medical support available.
- Ask about side effects and aftercare: A legitimate provider will explain potential risks, side effects, and aftercare instructions before proceeding.
- Report suspicious products or practices: If you encounter a product or clinic offering injectable “cosmetics” without proper regulatory approval, report it to the CDSCO or your state’s drug control authority.
📋 The Bigger Picture: CDSCO’s Regulatory Tightening in 2026
This directive is part of a broader pattern of CDSCO regulatory enforcement in 2026. Earlier this year, the regulator also:
- Intensified crackdowns on unauthorised sale of GLP-1 weight-loss drugs (as reported by Business Standard, March 2026)
- Flagged 168 medicines as “Not of Standard Quality” in March 2026 alone (ETV Bharat, April 2026)
- Shuffled 95 officials to combat regulatory capture (Whalesbook, April 2026)
- Issued warnings against indirect promotion of prescription weight-loss drugs (Livemint, March 2026)
- Tightened oversight on semaglutide products following counterfeit alerts (Whalesbook, July 2026)
Together, these actions signal that the CDSCO is actively strengthening its oversight of both pharmaceutical products and their marketing — a positive step for consumer safety in India’s healthcare landscape.
For consumers seeking verified and reliable pharmaceutical products and distributors, refer to the IMSDA’s verified member directory for a list of trusted suppliers.
For more information, contact IMSDA at contact@indiamedicine.org.